治疗急性缺血性脑梗死3种用药方案的药物经济学分析

摘要

目的：探讨银杏达莫、脉络宁和丹参酮ⅡA磺酸钠分别联合依达拉奉治疗急性缺血性脑梗死的药物经济学效果。方法：运用回顾性调查法，筛选出符合要求的61例急性缺血性脑梗死患者，采取的用药方案为A组（银杏达莫＋依达拉奉）19例、B组（脉络宁＋依达拉奉）21例、C组（丹参酮ⅡA磺酸钠＋依达拉奉）21例，14 d后观察各组疗效并计算治疗成本，进行药物经济学评价。结果：A组、B组、C组治疗急性缺血性脑梗死的成本分别为7964.88元、7012.81元、9636.82元；成本-效果比分别为94.55、105.19、120.91。结论：与B组和C组相比，A组是治疗急性缺血性脑梗死的最佳用药方案。%Objective: To observe the pharmacoeconomic effects of Ginkgo Leaf Extract and Dipyri-damole injection, Mailuoning injection and Tanshinone ⅡA Sulfonic Acid Natrium injection, joined up with Edaravone injection separately, for acute ischemic cerebral infarction(ACI). Methods: A total of 61 cases of ACI were divided into group A (Ginkgo Leaf Extract and Dipyridamole injection + Edaravone injection), 19; group B (Mailuoning injection + Edaravone injection), 21; and group C (Tanshinone ⅡA Sulfonic Acid Natrium injection+ Edaravone injection), 21. The curative efficacies were observed to analyze cost-effective-ness after 14 days of treatment. Results: The costs of group A, B and C were RMB 7964.88, 7012.81 and 9636.82 yuan, respectively. The cost-effectiveness ratios were 94.55, 105.19 and 120.91, respectively. Con-clusion: Compared with Group B and Group C,Group A is the optimal regime in the treatment of ACI.